Da Xie
谢达
Da Xie (谢达) is a vice president at FreeS Fund (峰瑞资本), where he invests in biotech and healthcare innovation . He identifies as a biopharma investor focused on clinically differentiated technologies, with particular interest in frontier and interdisciplinary areas . His coverage spans next-generation immunotherapy, epigenetics, and AI healthcare , and he has represented FreeS at research events and founder conferences alongside managing partner Jiong Shen . All sourcing here comes from FreeS Fund's own published materials; elsewhere's corpus does not contain independent editorial coverage of him.
AI-generated — may contain errors, please verify.
Coverage
Is AI Healthcare Having Its DeepSeek Moment? | Frees VC Research
AI healthcare is becoming an open secret.
How to Seize the Development Opportunities in Next-Generation Immunotherapy? | See You in Shanghai on September 19
Welcome to sign up and participate
AI Virtual Cells: Exploring Digital Life | FreeS Fund Report
Why We're Bullish on AI Virtual Cells
World Book Day | The Books That Give Us "High Energy"
Crossover Book Recommendations from Investors and Business Writers
What Are Top Overseas Chinese Students Thinking About When It Comes to Entrepreneurship and Investing? | FreeS Fund Dialogue
How do we make sense of the business world and think about the future?
Calico Cats, Bees, and the Dutch Hunger Winter — Unpacking the "Card-Playing Tricks" of Gene Expression | FreeS Fund Report 32
What are the startup and investment opportunities in the field of epigenetics?
How Can We Further Explore the Human Body's "Smartest" Organ? | FreeS Research Institute
A Few Things About Exploring the Brain
